BMY - Bristol-Myers Squibb Co.
(NaN%)
SNP 500
Sell
Weak Growth●Earnings/Profit is Negative
26%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 2.93%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -14.06%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.16
Debt Ratio is 0.82
Current Debt to Net Income Ratio is 2.1
Total Debt to Total Assets Ratio is 0.59
Cash Flow is MODERATE
Cash from Operations Growth is 19.52%
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Bristol-Myers Squibb Co. (BMY) - https://www.bms.com/
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Giovanni Caforio
Employees - 34,300
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.